A Phase II Study of CMV-Immune T cells for the Treatment of Cytomegalovirus Infection after Stem Cell Transplantation

Full Title

A Phase II Trial of Primary Transplant Donor Derived CMVpp65 specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia after Allogeneic Hematopoietic Stem Cell Transplantation


Cytomegalovirus (CMV) is a potential complication after stem cell transplantation. There are drugs used to treat CMV, but in some patients the virus has become resistant to these drugs, or the patient cannot tolerate them. In these cases, giving infusions of T cells (white blood cells) that are immune to CMV may be a potentially effective treatment.

In this study, researchers are evaluating the effectiveness of giving CMV-immune T cells to patients with persistent CMV infection after stem cell transplantation. The T cells are donated either by the patient’s stem cell donor, or — in the case of patients whose donors don’t have CMV-immune stem cells — they are donated by a “third party” whose T cells are immune to CMV. The T cells contributed by the donor are grown and “taught” in the laboratory how to attack CMV.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CMV infection after stem cell transplantation which is not responding to conventional CMV treatment.
  • Patients of all ages are eligible to participate.

For more information about this study and to inquire about eligibility, please contact Dr. Susan Prockop at 212-639-6715.





Disease Status

Newly Diagnosed & Relapsed/Refractory